Program
plozasiran
Also written as “Plozasiran Injection”, “ARO-APOC3” and “Plozasiran”.
Its studies are mostly in Hypertriglyceridemia · Dyslipidemias · Hyperlipoproteinemia Type I, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 102 open or running | phase 3since Oct 11, 2021 | Dec 19, 2018 | Jul 2028phase 3 · NCT06822790 |
| Visirna Therapeutics HK | 20 open or running | phase 3since May 31, 2023 | Feb 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2018First study: phase 1 study in HypertriglyceridemiaNew to Arrowhead PharmaceuticalsArrowhead Pharmaceuticals · NCT03783377 · 112 enrolled · Australia, Canada, New Zealand
- Jan 19, 2021Phase 2 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT04720534 · 229 enrolled · United States, Australia, Canada and more
- Aug 3, 2021Phase 2 study in Mixed DyslipidemiaArrowhead Pharmaceuticals · NCT04998201 · 353 enrolled · United States, Australia, Canada and more
- Oct 11, 2021Phase 3 study in Hyperlipoproteinemia Type IArrowhead Pharmaceuticals · NCT05089084 · 75 enrolled · United States, Argentina, Australia and more
- Jun 7, 2022Phase 2 study in DyslipidemiasArrowhead Pharmaceuticals · NCT05413135 · 418 enrolled · United States, Australia, Canada and more
- Feb 14, 2023Visirna Therapeutics HK's first study: phase 1 study in Healthy Adult VolunteersNew to Visirna Therapeutics HKVisirna Therapeutics HK · NCT05757596 · 24 enrolled · China
- May 31, 2023Phase 3 study in Familial hyperchylomicronemia syndromeVisirna Therapeutics HK · NCT05902598 · 37 enrolled · China
- Mar 29, 20243 phase 3 studies in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06347133, NCT06347016, NCT06347003
- Feb 7, 2025Phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06822790 · 710 enrolled · United States, Argentina, Australia and more
- Mar 12, 2025Phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06880770 · 288 planned · United States, Argentina, Austria and more
Ahead
- Jul 2028Primary completion: phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06822790
- Mar 2029Primary completion: phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06880770
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06880770Hypertriglyceridemia · United States, Argentina, Austria and more | 3 | Recruiting | Arrowhead Pharmaceuticals | Mar 2029 | 288 |
| NCT06822790Hypertriglyceridemia · United States, Argentina, Australia and more | 3 | Active, not recruiting | Arrowhead Pharmaceuticals | Jul 2028 | 710 |
| NCT06347133Hypertriglyceridemia · United States, Argentina, Australia and more | 3 | Completed | Arrowhead Pharmaceuticals | Jun 1, 2026 | 1,456 |
| NCT06347016Hypertriglyceridemia · United States, Argentina, Brazil and more | 3 | Completed | Arrowhead Pharmaceuticals | Jun 17, 2026 | 311 |
| NCT06347003Hypertriglyceridemia · United States, Argentina, Australia and more | 3 | Completed | Arrowhead Pharmaceuticals | Jun 12, 2026 | 446 |
| NCT05902598Familial hyperchylomicronemia syndrome · China | 3 | Completed | Visirna Therapeutics HK | Nov 26, 2024 | 37 |
| NCT05757596Healthy Adult Volunteers · China | 1 | Completed | Visirna Therapeutics HK | Sep 25, 2023 | 24 |
| NCT05413135Dyslipidemias · United States, Australia, Canada and more | 2 | Completed | Arrowhead Pharmaceuticals | Sep 22, 2025 | 418 |
| NCT05089084Hyperlipoproteinemia Type I · United States, Argentina, Australia and more | 3 | Completed | Arrowhead Pharmaceuticals | Apr 29, 2024 | 75 |
| NCT04998201Mixed Dyslipidemia · United States, Australia, Canada and more | 2 | Completed | Arrowhead Pharmaceuticals | Feb 10, 2023 | 353 |
| NCT04720534Hypertriglyceridemia · United States, Australia, Canada and more | 2 | Completed | Arrowhead Pharmaceuticals | Mar 9, 2023 | 229 |
| NCT03783377Hypertriglyceridemia · Australia, Canada, New Zealand | 1 | Completed | Arrowhead Pharmaceuticals | Feb 11, 2021 | 112 |
How it is read
Names in the registry
- “Plozasiran Injection”, 4 entries
- “ARO-APOC3”, 4 entries
- “Plozasiran”, 3 entries
- “VSA001 injection”, 1 entry
Codes read as this program: VSA001.
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 7 studies
- Dyslipidemias, 2 studies
- Hyperlipoproteinemia Type I, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.